Recent Media Coverage

Globes - Israel's Business Arena

June
2011

Teva and CEL-SCI launch Israel cancer treatment trial

Globes brings its unrivaled coverage of Israeli business to some 45,000 subscribers representing Israel's elite in management, investment, technology, law, accounting, and marketing. From the wealth of material in Globes, the English website team selects for translation the news and features that will matter most to English speaking readers.

AsianScientist.com

June
2011

CEL-SCI Starts Phase III Clinical Trials For Head And Neck Cancer In Taiwan

AsianScientist.com is dedicated to providing students, post-docs, researchers, healthcare professionals, government agencies, and educators with timely, close-to-the-scene information and news about Asia.

	North Mississippi Medical Center
March 2011	Press Release - World-Wide Clinical Drug Trial Begins in Tupelo

	The Washington Post
February 2011	CEL-SCI has faced challenges in biotech market but sees hope in tumor treatment

BioTuesdays

January
2011

CEL-SCI on cusp of cancer game-changer

BioTuesdays goal is to give great, but not necessarily big or well known, healthcare companies and their stories the exposure that they deserve.

NOVATEK International

April
2010

CEL-SCI Goes Live with Novatek's Environmental Monitoring LIMS Software (NOVA-EM)

Since 1996, Novatek International has been providing a new breed of all-encompassing, process-driven LIMS software solutions that target the pharmaceutical, biotech and other health-care industries.

Technology Review

November
24, 2009

Arming the Immune System against H1N1: Researchers are working to treat pandemic flu by recruiting a patient's own immune cells.

Technology Review and Technologyreview.com are published by Technology Review Inc., an independent media company owned by the Massachusetts Institute of Technology. The oldest technology magazine in the world (est. 1899), Technology Review aims to promote the understanding of emerging technologies and to analyze their commercial, social, and political impacts.

Investment U

October
7, 2009

The Next Big Thing In Health Care: How to Profit From Immunotherapy & Regenerative Medicine

Founded in 1999, the goal of Investment U is to give you impartial, no-nonsense advice on how to build long-lasting wealth. Our mission is to analyze and discuss all the important financial tools at your disposal.

	Washington Business Journal
September 16, 2009	CEL-SCI to begin H1N1 treatment trial

	Richmond Times-Dispatch
September 2, 2009	Virginia Economy: Let's Be Sure Biotech Has a Bright Future Op Ed by Geert Kersten, CEO of CEL-SCI Corporation

	Washington Business Journal
August 20, 2008	Cel-Sci lets Teva sell cancer drug

Careers